Athira gets positive interim analysis for Alzheimer's drug fosgonimeton, study continues

LeonaBio, Inc.

Independent data monitoring committee recommended continuation of LIFT-AD after unblinded interim analysis.
Adding fewer than 150 patients (total <300 with no background therapy) will power study for primary endpoint.
Interim analysis in ~100 patients not on background therapy corroborated prior ACT-AD Phase 2 findings.
Company targets enrollment completion mid-2023 and topline data in early 2024.
CEO cites strong balance sheet to execute through key data readouts.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.